Covered recipient · General Payments record
ROBERT A RICE
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2019–2024
$7,764.69
- Reported across 455 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $363.56 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Neurelis, Inc. | $85.43 | 3 |
| PFIZER INC. | $61.98 | 3 |
| Astellas Pharma US Inc | $54.78 | 2 |
| Novo Nordisk AS | $40.29 | 2 |
| Acerta Pharma LLC | $32.06 | 2 |
| ABBVIE INC. | $28.26 | 2 |
| E.R. Squibb & Sons, L.L.C. | $24.67 | 1 |
| Phathom Pharmaceuticals, Inc. | $20.57 | 1 |
| GlaxoSmithKline, LLC. | $15.52 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $15.11 | 04/10/2024 | Food and Beverage | Undisputed | 06/30/2026 | 1105944105 | CMS |
| ABBVIE INC. | $13.15 | 05/07/2024 | Food and Beverage | Undisputed | 06/30/2026 | 1105944107 | CMS |
| Astellas Pharma US Inc | $32.95 | 02/21/2024 | Food and Beverage | Undisputed | 06/30/2026 | 1139313194 | CMS |
| Astellas Pharma US Inc | $21.83 | 05/08/2024 | Food and Beverage | Undisputed | 06/30/2026 | 1139333816 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.60 | 01/27/2024 | Food and Beverage | Undisputed | 06/30/2026 | 1104221141 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.46 | 03/06/2024 | Food and Beverage | Undisputed | 06/30/2026 | 1104647347 | CMS |
| E.R. Squibb & Sons, L.L.C. | $24.67 | 02/06/2024 | Food and Beverage | Undisputed | 06/30/2026 | 1101698462 | CMS |
| GlaxoSmithKline, LLC. | $15.52 | 02/17/2024 | Food and Beverage | Undisputed | 06/30/2026 | 1116525336 | CMS |
| Neurelis, Inc. | $25.33 | 01/25/2024 | Food and Beverage | Undisputed | 06/30/2026 | 1145652172 | CMS |
| Neurelis, Inc. | $37.71 | 02/27/2024 | Food and Beverage | Undisputed | 06/30/2026 | 1145652174 | CMS |
| Neurelis, Inc. | $22.39 | 04/25/2024 | Food and Beverage | Undisputed | 06/30/2026 | 1145652176 | CMS |
| Novo Nordisk Inc | $21.32 | 01/10/2024 | Food and Beverage | Undisputed | 06/30/2026 | 1096733140 | CMS |
| Novo Nordisk Inc | $18.97 | 02/28/2024 | Food and Beverage | Undisputed | 06/30/2026 | 1096712658 | CMS |
| PFIZER INC. | $24.04 | 03/20/2024 | Food and Beverage | Undisputed | 06/30/2026 | 1131301669 | CMS |
| PFIZER INC. | $18.48 | 03/29/2024 | Food and Beverage | Undisputed | 06/30/2026 | 1132016039 | CMS |
| PFIZER INC. | $19.46 | 05/15/2024 | Food and Beverage | Undisputed | 06/30/2026 | 1131554712 | CMS |
| Phathom Pharmaceuticals, Inc. | $20.57 | 02/15/2024 | Food and Beverage | Undisputed | 06/30/2026 | 1151115881 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.